108 related articles for article (PubMed ID: 9613747)
1. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease.
Pang CP; Zhang J; Woo J; Chan D; Law LK; Tong SF; Kwok T; Kay R
Mov Disord; 1998 May; 13(3):529-32. PubMed ID: 9613747
[TBL] [Abstract][Full Text] [Related]
2. [Association between the debrisoquine hydroxylase gene polymorphism and the genetic susceptibility of Parkinson's disease].
Tao E; Liu Z; Chen B; Pan X; Shao M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Oct; 15(5):281-3. PubMed ID: 9758873
[TBL] [Abstract][Full Text] [Related]
3. Association between the oxidative polymorphism and early onset of Parkinson's disease.
Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine hydroxylase polymorphism in familial and sporadic Parkinson's disease.
Planté-Bordeneuve V; Davis MB; Maraganore DM; Marsden CD; Harding AE
Mov Disord; 1994 May; 9(3):337-9. PubMed ID: 7913740
[TBL] [Abstract][Full Text] [Related]
5. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families.
Lucotte G; Turpin JC; Gérard N; Panserat S; Krishnamoorthy R
Am J Med Genet; 1996 Jul; 67(4):361-5. PubMed ID: 8837703
[TBL] [Abstract][Full Text] [Related]
6. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
Christensen PM; Gøtzsche PC; Brøsen K
Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease.
Elbaz A; Levecque C; Clavel J; Vidal JS; Richard F; Amouyel P; Alpérovitch A; Chartier-Harlin MC; Tzourio C
Ann Neurol; 2004 Mar; 55(3):430-4. PubMed ID: 14991823
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
[TBL] [Abstract][Full Text] [Related]
10. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease.
Grimes DA; Han F; Panisset M; Racacho L; Xiao F; Zou R; Westaff K; Bulman DE
Mov Disord; 2006 Jul; 21(7):906-9. PubMed ID: 16532445
[TBL] [Abstract][Full Text] [Related]
11. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
12. [Association between cytochrome P-450 enzyme gene polymorphisms and Parkinson's disease].
Wang J; Liu Z; Chen B
Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):585-7. PubMed ID: 11798822
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine hydroxylase gene polymorphism in neurofibromatosis type 1.
Wundrack I; Sasiadek M; Blin N
Anticancer Res; 1997; 17(6D):4515-7. PubMed ID: 9494560
[TBL] [Abstract][Full Text] [Related]
14. Association analysis of a polymorphism of the monoamine oxidase B gene with Parkinson's disease in a Japanese population.
Morimoto Y; Murayama N; Kuwano A; Kondo I; Yamashita Y; Mizuno Y
Am J Med Genet; 1995 Dec; 60(6):570-2. PubMed ID: 8825899
[TBL] [Abstract][Full Text] [Related]
15. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
Kurth MC; Kurth JH
Am J Med Genet; 1993 Oct; 48(3):166-8. PubMed ID: 8291573
[TBL] [Abstract][Full Text] [Related]
16. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
17. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease.
Deng Y; Newman B; Dunne MP; Silburn PA; Mellick GD
Ann Neurol; 2004 Jun; 55(6):897. PubMed ID: 15174030
[No Abstract] [Full Text] [Related]
18. [Association between estrogen receptor beta gene polymorphisms and Parkinson disease].
Chen RJ; Zhang BS; Wang SM
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1185-8. PubMed ID: 18844113
[TBL] [Abstract][Full Text] [Related]
19. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
Bordet R; Broly F; Destée A; Libersa C
Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
[No Abstract] [Full Text] [Related]
20. Genetic polymorphism and Parkinson's disease in Taiwan: study of debrisoquine 4-hydroxylase (CYP2D6).
Lo HS; Chen CH; Hogan EL; Kao KP; Wang V; Yan SH
J Neurol Sci; 1998 Jun; 158(1):38-42. PubMed ID: 9667775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
